CAJ | 학술논문

右丙亚胺是作用位点专一的心脏防护药物.能够有效预防蒽环类抗肿瘤药引起的心脏毒性.右丙亚胺已被广泛应用于接受蒽环类抗肿瘤药化疔的患者.临床研究表明,静脉应用右丙亚胺能够显著降低葸环类抗肿瘤药引起的充血性心力衰竭和严重心脏意外.其不良反应非常小,患者易于耐受.到目前为止,是唯一有效地能够预防蒽环类抗肿瘤药引起的心脏毒性的药物,推荐临床使用.
우병아알시작용위점전일적심장방호약물.능구유효예방은배류항종류약인기적심장독성.우병아알이피엄범응용우접수은배류항종류약화정적환자.림상연구표명,정맥응용우병아알능구현저강저사배류항종류약인기적충혈성심력쇠갈화엄중심장의외.기불량반응비상소,환자역우내수.도목전위지,시유일유효지능구예방은배류항종류약인기적심장독성적약물,추천림상사용.
Cardioxane is a site-specific cardioprotective agent that effectively prevents anthraeycline-induced cardiac toxicity.Cardioxane is approved for use in a wider range of patients with advanced cancer re-ceiving anthracyclines.As shown in clinical trials, intravenous cardioxane significantly reduces the incidence of anthracycline-induced congestive heart failure (CHF) and severe cardiac events.The drug is generally well tol-elated and has a tolerability profile similar to that of placebo in cancer patients undergoing anthraeycline-based chemotherapy.Cardioxane is the only cardioproteetive agent with proven efficacy in cancer patients receiving anthracycline chemotherapy and is a valuable option for the prevention of cardiotoxicity in this patients popula-tion.